ReviewCurrent atherosclerosis reports2021
Diabetes, Lipids, and CV Risk.
Review in Current atherosclerosis reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Fermented dairy product consumption and blood lipid levels in healthy adults: a systematic review.Frontiers in nutrition · 2025Pooled it
- Review
- Erythrocyte Membrane Fingerprints in the Veterinary Field: The Importance of Membrane Profiling and Its Application in Companion Animals.Biomolecules · 2025Review
- Diabetes is the missing link between cardiometabolic index and gallstones: a large cross-sectional study.Scientific reports · 2025Article
- Association between serum uric acid and dyslipidaemia in type 2 diabetes: a cross-sectional study.BMJ open · 2025Article
- Associations between non-traditional lipid parameters and normoglycemic reversion in Chinese adults with prediabetes: a retrospective analysis.Frontiers in endocrinology · 2025Article
- Association between organophosphorus insecticides exposure and osteoarthritis in patients with arteriosclerotic cardiovascular disease.BMC public health · 2024Article
- Diabetes Mellitus Mediates the Relationship Between Atherogenic Index of Plasma and Gallstones: A Population-Based Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Combined impact of elevated C-reactive protein levels and dyslipidemia on stroke: a CHNS prospective cohort study.Frontiers in public health · 2024Article
- Health benefits and risks of fermented foods-the PIMENTO initiative.Frontiers in nutrition · 2024Review
- Oxidative stress regulates glycogen synthase kinase-3 in lymphocytes of diabetes mellitus patients complicated with cerebral infarction.Open medicine (Warsaw, Poland) · 2024Article
- Impact of intensive hypertension criteria on multimorbidity prevalence and patterns in a multi-ethnic Chinese population.Frontiers in public health · 2024Article
- The foundations and development of lipidomics.Journal of lipid research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDiabetes is often associated with diabetic dyslipidemia. Both hyperglycemia and disorders of lipid metabolism strongly contribute to development of atherosclerosis, the crucial factor of cardiovascular disease. The aim of the manuscript is to summarize possible treatment to reduce cardiovascular risk. RECENT
findingsMaximal cardiovascular risk reduction is maintained by targeting more pathologic disturbances together. While antihypertensive treatment has not changed much recently, novel PCSK9 inhibitors have significantly improved management of dyslipidemia. Similarly, modern antihyperglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) show both significant metabolic effects and cardiovascular benefits. Diabetes treatment is no longer glucocentric. Apart from glucose management, there are effective pharmacologic tools for significant reduction of cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.